Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of.
Theratechnologies Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
− FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than a Decade− FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free.
Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved FRUZAQLA fruquintinib an oral targeted therapy for adults with metastatic colorectal cancer mCRC who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antiVEGF therapy and if RAS wildtype and medically appropriate an antiEGFR therapy.
OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and only selective